RU2633505C2 - Фармацевтическая композиция для лечения и/или профилактики рака - Google Patents

Фармацевтическая композиция для лечения и/или профилактики рака Download PDF

Info

Publication number
RU2633505C2
RU2633505C2 RU2014138038A RU2014138038A RU2633505C2 RU 2633505 C2 RU2633505 C2 RU 2633505C2 RU 2014138038 A RU2014138038 A RU 2014138038A RU 2014138038 A RU2014138038 A RU 2014138038A RU 2633505 C2 RU2633505 C2 RU 2633505C2
Authority
RU
Russia
Prior art keywords
antibody
caprin
cancer
seq
antibodies
Prior art date
Application number
RU2014138038A
Other languages
English (en)
Russian (ru)
Other versions
RU2014138038A (ru
Inventor
Синити КОБАЯСИ
Фумиеси ОКАНО
Таканори САИТО
Original Assignee
Торэй Индастриз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Торэй Индастриз, Инк. filed Critical Торэй Индастриз, Инк.
Publication of RU2014138038A publication Critical patent/RU2014138038A/ru
Application granted granted Critical
Publication of RU2633505C2 publication Critical patent/RU2633505C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
RU2014138038A 2012-02-21 2013-02-21 Фармацевтическая композиция для лечения и/или профилактики рака RU2633505C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012035491 2012-02-21
JP2012-035491 2012-02-21
PCT/JP2013/054345 WO2013125640A1 (ja) 2012-02-21 2013-02-21 癌の治療及び／又は予防用医薬組成物

Publications (2)

Publication Number Publication Date
RU2014138038A RU2014138038A (ru) 2016-04-10
RU2633505C2 true RU2633505C2 (ru) 2017-10-12

Family

ID=49005817

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014138038A RU2633505C2 (ru) 2012-02-21 2013-02-21 Фармацевтическая композиция для лечения и/или профилактики рака

Country Status (17)

Country Link
US (1) US9266958B2 (show.php)
EP (1) EP2824114B1 (show.php)
JP (1) JP6187258B2 (show.php)
KR (1) KR102009236B1 (show.php)
CN (1) CN104114583B (show.php)
AU (1) AU2013223147B2 (show.php)
BR (1) BR112014021103A2 (show.php)
CA (1) CA2865020C (show.php)
DK (1) DK2824114T3 (show.php)
ES (1) ES2739380T3 (show.php)
HU (1) HUE045461T2 (show.php)
IN (1) IN2014KN01716A (show.php)
MX (1) MX360211B (show.php)
PL (1) PL2824114T3 (show.php)
PT (1) PT2824114T (show.php)
RU (1) RU2633505C2 (show.php)
WO (1) WO2013125640A1 (show.php)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2325648E (pt) 2008-08-05 2014-06-24 Toray Industries Método para detetar cancro
JP5691172B2 (ja) 2008-08-05 2015-04-01 東レ株式会社 癌の治療及び予防用医薬組成物
CA2788718C (en) * 2010-02-04 2019-05-21 Shinichi Kobayashi Caprin-1 antibody for treating and/or preventing cancer
KR102041832B1 (ko) * 2011-08-04 2019-11-08 도레이 카부시키가이샤 췌장암의 치료 및/또는 예방용 의약 조성물
RU2624040C2 (ru) 2011-08-04 2017-06-30 Торэй Индастриз, Инк. Способ обнаружения рака поджелудочной железы
RU2631804C2 (ru) 2012-02-21 2017-09-26 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения или профилактики рака
RU2649802C2 (ru) 2012-03-30 2018-04-04 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или предотвращения рака желчного пузыря
ES2656620T3 (es) * 2012-03-30 2018-02-27 Toray Industries, Inc. Composición farmacéutica para el tratamiento y/o la prevención del cáncer de hígado
DK2876447T3 (da) 2012-07-19 2020-02-24 Toray Industries Fremgangsmåde til detektering af cancer
DK2876446T3 (en) 2012-07-19 2019-03-11 Toray Industries Method for detecting cancer
US9862774B2 (en) 2013-08-09 2018-01-09 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
ES2990113T3 (es) 2016-07-07 2024-11-28 The Board Of Trustees Of The Leland Stanfordjunior Univ Conjugados de adyuvantes de anticuerpos
RU2766586C2 (ru) 2016-10-28 2022-03-15 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или предупреждения злокачественной опухоли
CN111936164B (zh) 2018-03-30 2024-09-17 东丽株式会社 癌的治疗和/或预防用药物组合物
CN113993549A (zh) 2019-03-15 2022-01-28 博尔特生物治疗药物有限公司 靶向her2的免疫缀合物
EP3983082A1 (en) 2019-06-13 2022-04-20 Bolt Biotherapeutics, Inc. Aminobenzazepine compounds, immunoconjugates, and uses thereof
MX2022003740A (es) 2019-09-30 2022-05-02 Bolt Biotherapeutics Inc Inmunoconjugados de aminobenzazepina unidos a amida y usos de estos.
EP4048315B1 (en) 2019-10-25 2025-03-12 Bolt Biotherapeutics, Inc. Thienoazepine immunoconjugates, and uses thereof
JPWO2021182574A1 (show.php) * 2020-03-12 2021-09-16
US20230140155A1 (en) 2020-03-12 2023-05-04 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
US20230129035A1 (en) 2020-03-12 2023-04-27 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
US20230165957A1 (en) 2020-03-12 2023-06-01 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
CA3175277A1 (en) 2020-03-12 2021-09-16 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
WO2021226440A1 (en) 2020-05-08 2021-11-11 Bolt Biotherapeutics, Inc. Elastase-substrate, peptide linker immunoconjugates, and uses thereof
IL300316A (en) 2020-08-13 2023-04-01 Bolt Biotherapeutics Inc Immune conjugates of pyrazolozapines and their uses
WO2022270524A1 (ja) 2021-06-23 2022-12-29 東レ株式会社 癌の治療及び／又は予防のための医薬品
KR20240024074A (ko) 2021-06-23 2024-02-23 도레이 카부시키가이샤 암의 치료 및/또는 예방을 위한 의약품
JPWO2023008462A1 (show.php) 2021-07-27 2023-02-02
AU2022319362A1 (en) 2021-07-27 2024-02-29 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
AU2022316644A1 (en) 2021-07-27 2024-02-29 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
KR20240051956A (ko) 2021-09-03 2024-04-22 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
EP4422697A1 (en) 2021-10-29 2024-09-04 Bolt Biotherapeutics, Inc. Tlr agonist immunoconjugates with cysteine-mutant antibodies, and uses thereof
WO2024005123A1 (ja) 2022-06-30 2024-01-04 東レ株式会社 癌の治療及び／又は予防用医薬組成物
JPWO2024043252A1 (show.php) 2022-08-24 2024-02-29
KR20250052368A (ko) 2022-08-24 2025-04-18 도레이 카부시키가이샤 암의 치료 및/또는 예방을 위한 의약품
WO2024043257A1 (ja) 2022-08-24 2024-02-29 東レ株式会社 癌の治療及び／又は予防のための医薬品
AU2023334696A1 (en) 2022-08-30 2025-02-27 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
WO2024048541A1 (ja) 2022-08-30 2024-03-07 東レ株式会社 癌の治療及び／又は予防のための医薬品
JPWO2024135809A1 (show.php) 2022-12-23 2024-06-27
WO2024173387A1 (en) 2023-02-14 2024-08-22 Bolt Biotherapeutics, Inc. Aza-benzazepine immunoconjugates, and uses thereof
WO2024186626A1 (en) 2023-03-03 2024-09-12 Bolt Biotherapeutics, Inc. Aza-bicyclic sting agonist immunoconjugates, and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010016527A1 (ja) * 2008-08-05 2010-02-11 東レ株式会社 癌の検出方法
WO2010016526A1 (ja) * 2008-08-05 2010-02-11 東レ株式会社 癌の治療及び予防用医薬組成物
RU2418587C1 (ru) * 2010-01-21 2011-05-20 Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Федерального Агентства по здравоохранению и социальному развитию" (ГОУ ВПО "НижГМА Росздрава") Способ лечения злокачественных опухолей головного мозга

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
HU221385B1 (en) 1994-07-13 2002-09-28 Chugai Pharmaceutical Co Ltd Reconstituted human antibody against human interleukin-8
US5698396A (en) 1995-06-07 1997-12-16 Ludwig Institute For Cancer Research Method for identifying auto-immunoreactive substances from a subject
WO2001032910A2 (en) 1999-10-29 2001-05-10 Human Genome Sciences, Inc. 27 human secreted proteins
FR2761994B1 (fr) 1997-04-11 1999-06-18 Centre Nat Rech Scient Preparation de recepteurs membranaires a partir de baculovirus extracellulaires
HUP0101160A2 (hu) 1998-04-03 2001-08-28 Chugai Seiyaku Kabushiki Kaisha Humán szöveti faktor (TF) elleni humanizált antitest és eljárás előállítására
US20030118599A1 (en) 1999-04-02 2003-06-26 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
TW200728465A (en) 1998-07-14 2007-08-01 Corixa Corp Compositions and methods for the therapy and diagnosis of prostate cancer
RU2234942C2 (ru) 1998-07-14 2004-08-27 Корикса Корпорейшн Выделенный опухолевый полипептид предстательной железы и кодирующий его полинуклеотид
US6969518B2 (en) 1998-12-28 2005-11-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6335170B1 (en) 1999-02-22 2002-01-01 Torben F. Orntoft Gene expression in bladder tumors
EP1187915A2 (en) 1999-04-02 2002-03-20 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
US6444425B1 (en) 1999-04-02 2002-09-03 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US20020006404A1 (en) 1999-11-08 2002-01-17 Idec Pharmaceuticals Corporation Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
HUP0500345A2 (hu) 2000-03-29 2005-07-28 Corixa Corporation Készítmények és alkalmazások tüdőrák kezelésére és diagnosztizálására
US7041870B2 (en) 2000-11-30 2006-05-09 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
US7919467B2 (en) 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US20040029114A1 (en) 2001-01-24 2004-02-12 Eos Technology, Inc. Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
RU2306952C2 (ru) 2001-01-31 2007-09-27 Байоджен Айдек Инк. Лечение в-клеточных злокачественных опухолей с использованием комбинации применений, связанных с антителами, уменьшающими количество b-клеток, и с иммуномодулирующими антителами
US20040236091A1 (en) 2001-03-28 2004-11-25 Chicz Roman M. Translational profiling
WO2002083070A2 (en) 2001-04-10 2002-10-24 Corixa Corporation Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
CN100448992C (zh) 2001-05-11 2009-01-07 麒麟医药株式会社 含人抗体λ轻链基因的人类人工染色体
WO2002092001A2 (en) 2001-05-11 2002-11-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030190640A1 (en) 2001-05-31 2003-10-09 Mary Faris Genes expressed in prostate cancer
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
CA2476518A1 (en) 2002-02-22 2003-09-04 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US20050003390A1 (en) 2002-05-17 2005-01-06 Axenovich Sergey A. Targets for controlling cellular growth and for diagnostic methods
WO2004007668A2 (en) 2002-07-12 2004-01-22 The Regents Of The University Of California Improved transporters and their uses
US20040126379A1 (en) 2002-08-21 2004-07-01 Boehringer Ingelheim International Gmbh Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents
EP2314676A1 (en) 2002-11-26 2011-04-27 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
CA2524173A1 (en) 2003-04-29 2004-11-11 Wyeth Methods for diagnosing aml and mds differential gene expression
WO2005005601A2 (en) 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2005007830A2 (en) 2003-07-14 2005-01-27 Mayo Foundation For Medical Education And Research Methods and compositions for diagnosis, staging and prognosis of prostate cancer
US20050032113A1 (en) 2003-07-17 2005-02-10 Mitsubishi Pharma Corporation Membrane protein library for proteome analysis and method for preparing same
EP2361929A1 (en) 2004-01-26 2011-08-31 Debiovision Inc. Neoplasm-specific polypeptides and their use
PT1735348E (pt) 2004-03-19 2012-07-24 Imclone Llc Anticorpo anti-receptor do factor de crescimento humano
EP1730191B1 (en) 2004-03-30 2011-07-06 Glaxo Group Limited Immunoglobulin binding hosm
WO2005100998A2 (en) 2004-04-16 2005-10-27 Europroteome Ag Membrane markers for use in cancer diagnosis and therapy
WO2006002378A2 (en) 2004-06-23 2006-01-05 Avalon Pharmaceuticals Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods
BRPI0518104B8 (pt) 2005-01-21 2021-05-25 Genentech Inc artigo industrializado e uso de anticorpo her2
EP1849002A4 (en) 2005-02-18 2008-08-20 Childrens Medical Center Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin
KR101310000B1 (ko) 2005-03-11 2013-09-25 싸이퍼젠 바이오시스템즈, 인코포레이티드 난소암 및 자궁내막암에 대한 바이오마커 : 헵시딘
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
US8014957B2 (en) 2005-12-15 2011-09-06 Fred Hutchinson Cancer Research Center Genes associated with progression and response in chronic myeloid leukemia and uses thereof
CA2642342A1 (en) 2006-02-14 2007-08-23 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
US20100015724A1 (en) 2006-08-17 2010-01-21 Peter Hornbeck Lysine acetylation sites
US20080107668A1 (en) 2006-08-30 2008-05-08 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
WO2008031041A2 (en) 2006-09-07 2008-03-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. Melanoma gene signature
WO2008059252A2 (en) 2006-11-15 2008-05-22 Oxford Biomedica (Uk) Limited Methods and composition fro t cell receptors which recognize 5t4 antigen
JP5663834B2 (ja) 2008-03-14 2015-02-04 東ソー株式会社 遺伝子組換え抗体の製造方法
SI2644204T1 (sl) 2008-03-18 2017-08-31 Genentech, Inc. Kombinacije konjugata protitelo proti HER2-zdravilo in pertuzumaba
ES2619322T3 (es) 2008-08-05 2017-06-26 Toray Industries, Inc. Agente inductor de inmunidad
EA032728B1 (ru) 2009-08-19 2019-07-31 Мерк Патент Гмбх Антитела для выявления комплексов интегрина в ffpe материале
EA026336B1 (ru) 2009-09-22 2017-03-31 Пробиоген Аг Клетка позвоночного или насекомого для продукции белка или липида, не содержащего фукозу или содержащего сниженное количество фукозы, и ее применения
CA2788718C (en) 2010-02-04 2019-05-21 Shinichi Kobayashi Caprin-1 antibody for treating and/or preventing cancer
BR112012018951C8 (pt) 2010-02-04 2020-06-23 Toray Industries anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica
HUE025678T2 (en) * 2010-02-04 2016-04-28 Toray Industries A pharmaceutical composition for the treatment and / or prevention of cancer
CN102834113B (zh) 2010-02-04 2016-03-02 东丽株式会社 癌的治疗和/或预防用药物组合物
RU2624029C2 (ru) 2010-02-04 2017-06-30 Торэй Индастриз, Инк. Лекарственный препарат для лечения и/или профилактики рака
EP2532365B1 (en) 2010-02-04 2016-05-04 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
WO2012005550A2 (ko) 2010-07-08 2012-01-12 강원대학교산학협력단 담낭암 치료용 약제학적 조성물 및 이를 이용한 담낭암의 성장, 전이 억제 및 치료 방법
ES2871092T3 (es) 2010-07-26 2021-10-28 Progastrine Et Cancers S A R L Métodos y composiciones para la terapia del cáncer de hígado
JP5565183B2 (ja) 2010-08-06 2014-08-06 宇部興産株式会社 フィルムの製造方法
RU2624040C2 (ru) 2011-08-04 2017-06-30 Торэй Индастриз, Инк. Способ обнаружения рака поджелудочной железы
CA2844042C (en) * 2011-08-04 2019-06-18 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
KR102041832B1 (ko) 2011-08-04 2019-11-08 도레이 카부시키가이샤 췌장암의 치료 및/또는 예방용 의약 조성물
ES2656620T3 (es) 2012-03-30 2018-02-27 Toray Industries, Inc. Composición farmacéutica para el tratamiento y/o la prevención del cáncer de hígado
RU2649802C2 (ru) 2012-03-30 2018-04-04 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или предотвращения рака желчного пузыря

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010016527A1 (ja) * 2008-08-05 2010-02-11 東レ株式会社 癌の検出方法
WO2010016526A1 (ja) * 2008-08-05 2010-02-11 東レ株式会社 癌の治療及び予防用医薬組成物
RU2418587C1 (ru) * 2010-01-21 2011-05-20 Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Федерального Агентства по здравоохранению и социальному развитию" (ГОУ ВПО "НижГМА Росздрава") Способ лечения злокачественных опухолей головного мозга

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SOLOMON S. et al., Distinct Structural Features of Caprin-1 Mediate Its Interaction with G3BP-1 and Its Induction of Phosphorylation of Eukaryotic Translation Initiation Factor 2α, Entry to Cytoplasmic Stress Granules, and Selective Interaction with a Subset of mRNAs, MOLECULAR AND CELLULAR BIOLOGY, 2007, Vol. 27, No. 6, p. 2324-2342. *

Also Published As

Publication number Publication date
KR20140130671A (ko) 2014-11-11
JP6187258B2 (ja) 2017-08-30
ES2739380T3 (es) 2020-01-30
HUE045461T2 (hu) 2019-12-30
CA2865020A1 (en) 2013-08-29
CN104114583A (zh) 2014-10-22
PL2824114T3 (pl) 2019-11-29
PT2824114T (pt) 2019-08-05
AU2013223147B2 (en) 2017-10-05
CA2865020C (en) 2021-01-26
US20150017172A1 (en) 2015-01-15
BR112014021103A8 (pt) 2018-01-23
KR102009236B1 (ko) 2019-08-09
EP2824114A1 (en) 2015-01-14
RU2014138038A (ru) 2016-04-10
MX2014009749A (es) 2014-11-14
BR112014021103A2 (pt) 2019-10-15
US9266958B2 (en) 2016-02-23
DK2824114T3 (da) 2019-07-29
EP2824114A4 (en) 2015-10-07
WO2013125640A1 (ja) 2013-08-29
MX360211B (es) 2018-10-24
AU2013223147A1 (en) 2014-09-11
CN104114583B (zh) 2019-11-19
JPWO2013125640A1 (ja) 2015-07-30
IN2014KN01716A (show.php) 2015-10-23
EP2824114B1 (en) 2019-05-22

Similar Documents

Publication Publication Date Title
RU2633505C2 (ru) Фармацевтическая композиция для лечения и/или профилактики рака
RU2631804C2 (ru) Фармацевтическая композиция для лечения или профилактики рака
RU2632645C2 (ru) Фармацевтическая композиция для лечения и/или профилактики рака
RU2639522C2 (ru) Фармацевтическая композиция для лечения и/или профилактики рака
RU2611197C2 (ru) Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли
RU2595400C2 (ru) Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли
RU2610428C2 (ru) Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли
RU2624049C2 (ru) Фармацевтическая композиция для лечения и профилактики злокачественной опухоли
RU2678138C2 (ru) Фармацевтическая композиция для лечения и/или профилактики рака
RU2641260C2 (ru) Фармацевтическая композиция для лечения и профилактики злокачественной опухоли
BR112014021101B1 (pt) Anticorpo, composição farmacêutica e uso de um anticorpo ou seu fragmento, ou de uma composição